US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc. (NASDAQ: STOK), securing exclusive commercialization rights to zorevunersen, a drug for Dravet syndrome, in all territories outside the United States, Canada, and Mexico.
Drug Profile
Zorevunersen is an antisense oligonucleotide (ASO) targeting the SCN1A gene, the root cause of most Dravet syndrome cases. The drug is designed to modify the disease’s progression, addressing severe seizures and cognitive impairments.
Clinical Trial
Stoke plans to launch the global Phase III EMPEROR study in Q2 2024, with key data expected in H2 2027. The trial will support regulatory filings worldwide.
Financial Terms
Biogen will pay Stoke an upfront fee of USD 165 million and commit to USD 385 million in milestone payments. Biogen will also receive tiered royalties on net sales. The firms will share clinical development costs at a 30:70 ratio.-Fineline Info & Tech
Leave a Reply